A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
← catalyst calendarNCT06693531 · readout in 1,372 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →. With Sanofi.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
368actual
Sites
54
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-22 | actual | When the study began enrolling |
| Primary completion | 2030-05-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-05-22 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Eosinophilic Esophagitis (EoE)
Intervention
- Drug: dupilumab — also filed as DUPIXENT®, REGN668, SAR231893
Primary outcomes
what the primary-completion date above is the date OFDemographic characteristic of participants who receive dupilumab for EoE: Age
measured Baseline and up to 3 years after treatment initiation
Demographic characteristic of participants who receive dupilumab for EoE: Race
measured Baseline and up to 3 years after treatment initiation
Demographic characteristic of participants who receive dupilumab for EoE: Weight
measured Baseline and up to 3 years after treatment initiation
Demographic characteristic of participants who receive dupilumab for EoE: Height
measured Baseline and up to 3 years after treatment initiation
Disease characteristics of participants who receive dupilumab for EoE: Esophagogastroduodenoscopy (EGD)
measured Baseline and up to 3 years after treatment initiation
Disease characteristics of participants who receive dupilumab for EoE: Dilation/impaction history
measured Baseline and up to 3 years after treatment initiation
Disease characteristics of participants who receive dupilumab for EoE: Dietary interventions
measured Baseline and up to 3 years after treatment initiation
Disease characteristics of participants who receive dupilumab for EoE: Medical history
measured Baseline and up to 3 years after treatment initiation
EoE medication history of participant
measured Previous 1 year and up to 3 years after treatment initiation
Non-EoE medication history of participant
measured Previous 3 months and up to 3 years after treatment initiation
Prior dupilumab exposure history of participant
measured Baseline and up to 3 years after treatment initiation
Publications
- PMID 42100495 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed